On October 23, 2026, Arcus Biosciences completed a public offering of 16,428,572 shares of common stock, including the full exercise of the underwriters' option. The offering was priced at $17.50 per share, with the company receiving net proceeds of approximately $269.7 million. This funding will support Arcus's innovative cancer therapies. The offering was conducted under an effective registration statement with the SEC.
Who to call at Arcus Biosciences, and when
A new round usually means Arcus Biosciences is about to hire and buy. The teams that reach out first get the meeting.
An alert the day Arcus Biosciences raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Arcus Biosciences, from your own LinkedIn network
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Arcus Biosciences
Location
Hayward, California, United States
About
Arcus Biosciences, Inc. is a clinical-stage, global biopharmaceutical company, focused on developing differentiated molecules and combination therapies for people with cancer.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Arcus Biosciences raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
HaywardBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharma